Enanta Pharmaceuticals Awarded Three US Patents for Novel Macrolide Antibiotics.Business/Technology Editors & Health/Medical Writers BIOWIRE2K WATERTOWN, Mass.--(BUSINESS WIRE)--Oct. 9, 2002 Enanta Pharmaceuticals, Inc. (www.enanta.com), a chemistry-driven biopharmaceutical company developing macrolide antibiotics and immunosuppressants immunosuppressants, n.pl the agents that lower or reduce immune response; useful in organ transplant surgery to prevent organ rejection. Corticosteroid hormones given in large amounts; cytotoxic drugs, including antimetabolites and alkylating agents; , announced today that the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property has issued three U.S. Patents claiming novel classes of macrolide antibiotic compounds discovered by its scientists. The patents issued are: Number 6,436, 906, titled "9-Amino-14-Membered Macrolides Derived from Leucomycins," Number 6,440,942, titled "14-Membered Macrolides Derived from Leucomycins," and Number 6,462,026, titled "Bicyclic bi·cy·clic also bi·cy·cli·cal adj. 1. Consisting of or having two cycles. 2. Botany Composed of or arranged in two distinct whorls, as the petals of a flower. 3. Leucomycins." The patents describe distinct classes of macrolide compounds that possess antibacterial antibacterial /an·ti·bac·te·ri·al/ (-bak-ter´e-al) destroying or suppressing growth or reproduction of bacteria; also, an agent that does this. an·ti·bac·te·ri·al adj. activity toward Gram positive and Gram negative bacteria as well as macrolide resistant Gram positive pathogens. Enanta is actively engaged in macrolide antibiotic research and development. "A significant part of Enanta's R&D effort is focused on developing new generation macrolide antibiotics for the treatment of respiratory tract infections," said Spiros Jamas, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Enanta. "The issuance of three patents for novel macrolide compounds underscores Enanta's chemistry expertise and our goal of creating a broad intellectual property position." The macrolide antibiotic family, comprising 14-, 15- and 16-membered ring compounds, exhibits a wide-ranging catalog of characteristics such as, antibacterial spectrum, side-effects and bioavailability bioavailability /bio·avail·a·bil·i·ty/ (bi?o-ah-val?ah-bil´i-te) the degree to which a drug or other substance becomes available to the target tissue after administration. bi·o·a·vail·a·bil·i·ty n. . Enanta's patents relate to novel macrolide compounds, the processes for making them and methods for using them in the treatment of infections. "These issued patents enhance Enanta's initiative in macrolide development allowing the Company to continue to impact a significant disease area," stated Dr.Yat Sun Or, Enanta's senior vice president, research and development. "We anticipate that our research in macrolides will lead to the development of new and improved therapeutics for diseases with unmet global medical needs." About Enanta Headquartered in Watertown, Mass., Enanta Pharmaceuticals is using its breakthrough chemistry technology -- Drug Morphing(TM) and Peptide Morphing(R) -- to create new intellectual properties by transforming existing drugs, natural products, and biologically active peptides into novel, small-molecule drugs. The Company is initially focusing on new chemical entities derived from existing drugs that address significant unmet medical needs: (a) new-generation macrolide antibiotics to overcome bacterial resistance; and (b) anti-inflammatory drugs Anti-inflammatory drugs A class of drugs that lower inflammation and that includes NSAIDs and corticosteroids. Mentioned in: Antirheumatic Drugs for a variety of indications, including asthma, psoriasis and inflammatory bowel diseases inflammatory bowel disease n. Abbr. IBD Any of several incurable and debilitating diseases of the gastrointestinal tract characterized by inflammation and obstruction of parts of the intestine. . |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion